PBS updates

Leqvio (inclisiran)

inclisiran 284 mg/1.5 mL injection, 1.5 mL syringe · INJECTION · PBS code 14087K

STREAMLINED

What it costs

AU$1699.2 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2024-04-01.
  • • Repeats: 0.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Familial heterozygous hypercholesterolaemia


Continuing treatment with this drug or switching treatment from a monoclonal antibody inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication


Patient must have previously received PBS-subsidised treatment with this drug for this condition; or

Patient must have previously received PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication; AND

The treatment must be in conjunction with dietary therapy and exercise; AND

Patient must not be receiving concomitant PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner in consultation with a specialist physician.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Non-familial hypercholesterolaemia


Continuing treatment with this drug or switching treatment from a monoclonal antibody inhibiting proprotein coverase subtilisin kexin type 9 (PSCK9) for this PBS indication


Patient must have previously received PBS-subsidised treatment with this drug for this condition; or

Patient must have previously received PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication; AND

The treatment must be in conjunction with dietary therapy and exercise; AND

Patient must not be receiving concomitant PBS-subsidised treatment with a monoclonal antibody inhibiting proprotein convertase subtilisin kexin type 9 (PCSK9) for this PBS indication; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner in consultation with a specialist physician.

Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.